Innoviva subsidiary Entasis scores FDA nod for bacterial pneumonia combo drug Xacduro

In financial distress last May, AstraZeneca spinout Entasis Therapeutics sold out to holding company Innoviva for $113 million. A year later—to the day—Innoviva’s subsidiary has scored its first FDA approval.